Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial

Amir Hadanny1,2,3, Malka Daniel-Kotovsky1, Gil Suzin1, Rahav Boussi-Gross1, Merav Catalogn1, Kobi Dagan1, Yafit Hacho1, Ramzia Abu Hamed1, Efrat Sasson1, Gregory Fishlev1, Erez Lang1, Nir Polak1, Keren Doenyas1, Mony Friedman1, Sigal Tal4, Yonatan Zemel1, Yair Bechor1, Shai Efrati1,2,5,6

1The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel
2Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat-Gan, Israel
4Radiology Department, Shamir Medical Center, Zerifin, Israel
5Research and Development Unit, Shamir Medical Center, Zerifin, Israel
6Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel

Correspondence to: Amir Hadanny, Shai Efrati; email: amir.had@gmail.com, efratishai@outlook.com
Keywords: aging, cognitive, hyperbaric oxygen, perfusion, cerebral blood flow
Received: May 6, 2020 Accepted: June 9, 2020 Published: June 26, 2020

ABSTRACT

More than half of community-dwelling individuals sixty years and older express concern about declining cognitive abilities. The current study's aim was to evaluate hyperbaric oxygen therapy (HBOT) effect on cognitive functions in healthy aging adults.

A randomized controlled clinical trial randomized 63 healthy adults (>64) either to HBOT(n=33) or control arms(n=30) for three months. Primary endpoint included the general cognitive function measured post intervention/control. Cerebral blood flow (CBF) was evaluated by perfusion magnetic resonance imaging.

There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017). The most striking improvements were in attention (net effect size=0.745) and information processing speed (net effect size=0.788).

Voxel-based analysis showed significant cerebral blood flow increases in the HBOT group compared to the control group in the right superior medial frontal gyrus (BA10), right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8) and the right superior parietal gyrus (BA7).

In this study, HBOT was shown to induce cognitive enhancements in healthy aging adults via mechanisms involving regional changes in CBF. The main improvements include attention, information processing speed and executive functions, which normally decline with aging.

INTRODUCTION

More than half of community-dwelling individuals, sixty years and older, express concern about declining cognitive abilities [1]. Besides common pathological declines such as in Alzheimer’s dementia and mild cognitive impairments, normal cognitive aging is part of the normal aging process. Processing speed, conceptual reasoning, memory and problem-solving activities are the main domains which decline gradually over time [2]. Cerebrovascular dysfunction is an additional distinctive
A feature of aging that includes endothelial-dependent vasodilatation and regional decreases in cerebral blood flow (CBF) [3, 4]. Although not associated with a specific pathology, reduced regional CBF is associated with impaired cognitive functions [5, 6].

A growing body of research suggests several methods for cognitive enhancement and for improving the quality of life in both healthy and pathological states. Non pharmacological lifestyle interventions including exercise, healthy diets and cognitive training have shown positive effects if intensively performed [7, 8]. Unfortunately, so far, pharmacological interventions did not show significant improvements in cognitive performance in normal aging, and have significant risks for side effects [9].

Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen in an environmental pressure higher than one absolute atmospheres (ATA) to enhance the amount of oxygen dissolved in body’s tissues. Repeated intermittent hyperoxic exposures, has been shown to induce physiological effects which normally occur during hypoxia in a hyperoxic environment, including stem cells proliferation and generation of new blood vessels (angiogenesis) [10–13]. Angiogenesis is induced mainly in brain regions signaling ischemia or metabolic dysfunction [13–15]. In turn, neovascularization can enhance cerebral blood flow [14] and consequently improve the metabolic activity [13–15].

There is growing evidence from clinical studies that HBOT, utilized in a repeated daily sessions protocol, has neurotherapeutic effects which can improve cognitive functions in post-stroke, traumatic brain injury and anoxic brain damaged patients even years after the acute insult [15–19]. However, no study to date has examined HBOT’s neurocognitive effects in normal aging populations.

The aim of the current study was to evaluate whether HBOT affects cognitive function and brain perfusion in normal, non-pathological, aging adults.

**RESULTS**

Out of 100 individuals that were contacted for participation, 70 were eligible and signed an informed consent. Seven patients did not complete baseline assessments and were excluded. All 63 patients who completed baseline evaluations completed interventions. One patient did not complete the cognitive assessment post-HBOT and excluded from analysis (Figure 1). The baseline characteristics and comparability of the cohort are provided in Table 1. The HBOT arm patients were
### Figure 1. Participants flowchart.

### Table 1. Baseline characteristics.

|                      | Total      | Control    | HBOT       | P-value |
|----------------------|------------|------------|------------|---------|
| **N**                | 63 (100%)  | 33 (52.3%) | 30 (47.7%) |         |
| **Age (years)**      | 69.70±3.59 | 68.81±3.34 | 70.68±3.64 | 0.041   |
| **Males**            | 39 (61.9%) | 23 (69.7%) | 16 (53.3%) | 0.182   |
| **Right dominance**  | 57 (90.5%) | 2 (6.1%)   | 4 (13.3%)  | 0.326   |
| **Life partner**     | 55 (87.3%) | 29 (87.9%) | 26 (86.7%) | 0.885   |
| **Education years**  | 15.23±2.81 | 15.03±2.87 | 15.45±2.78 | 0.564   |
| **Working**          | 29 (46%)   | 16 (48.5%) | 13 (43.3%) | 0.682   |
| **Family history**   |            |            |            |         |
| Cognitive decline    | 23 (36.5%) | 8 (24.2%)  | 15 (50%)   | 0.034   |
| Cancer               | 31 (49.2%) | 16 (48.5%) | 15 (50%)   |         |
| Ischemic heart disease | 12 (19%)  | 4 (12.1%)  | 8 (26.7%)  | 0.202   |
| **Chronic medical conditions** |          |            |            |         |
| Atrial fibrillation  | 4 (6.3%)   | 0          | 4 (13.3%)  | 0.046   |
| Hypothyroidism       | 7 (11.1%)  | 3 (9.1%)   | 4 (13.3%)  | 0.593   |
| Obstructive sleep apnea | 3 (4.8%) | 0          | 3 (10%)    | 0.102   |
| Asthma               | 3 (4.8%)   | 2 (6.1%)   | 1 (3.3%)   | 1       |
| Benign prostatic hyperplasia | 14 (22.2%) | 7 (23.3%) | 7 (21.2%)  | 0.842   |
| Gastroesophageal reflux disease | 5 (7.9%) | 2 (6.1%) | 3 (10%)    | 0.662   |
| Osteoporosis         | 10 (15.9%) | 5 (15.2%)  | 5 (16.7%)  | 0.869   |
| Rheumatic arthritis  | 4 (6.3%)   | 3 (9.1%)   | 1 (3.3%)   | 0.614   |
| Osteoarthritis       | 11 (17.5%) | 4 (12.1%)  | 7 (23.3%)  | 0.325   |
| Diabetes mellitus    | 10 (15.9%) | 7 (21.2%)  | 3 (10%)    | 0.308   |
| Hypertension         | 14 (22%)   | 7 (21.2%)  | 7 (23.3%)  | 0.84    |
| Dyslipidemia         | 30 (47.6%) | 14 (42.4%) | 16 (53.3%) | 0.387   |
| Ischemic heart disease | 6 (9.5%) | 4 (12.1%)  | 2 (6.7%)   | 0.674   |
| History of smoking   | 24 (38.1%) | 14 (42.4%) | 10 (33.3%) | 0.458   |
| Smoking pack years   | 22.38±13.33| 21.21±10.75| 24.0±16.79 | 0.625   |
| Quit smoking years   | 23.96±12.36| 23.71±11.86| 24.3±13.68 | 0.912   |
| **Chronic medications** |          |            |            |         |
| Anti-aggregation      | 14 (22.2%) | 6 (18.2%)  | 8 (26.7%)  | 0.418   |
| ACE-Inhibitors/ARB blockers | 14 (22.2%) | 8 (24.2%) | 6 (20%)    | 0.686   |
| Beta blockers         | 11 (17.5%) | 6 (18.2%)  | 5 (16.7%)  | 0.874   |
| Calcium blockers      | 6 (9.5%)   | 3 (9.1%)   | 3 (10%)    | 1       |
| Alpha blockers        | 13 (20.6%) | 6 (18.2%)  | 7 (23.3%)  | 0.614   |
| Diuretics            | 3 (4.8%)   | 1 (3%)     | 2 (6.7%)   | 0.601   |
| Statins              | 19 (30.2%) | 9 (27.3%)  | 10 (33.3%) | 0.601   |
| Oral hypoglycemic    | 5 (7.9%)   | 4 (12.1%)  | 1 (3.3%)   | 0.357   |
| Bisphosphonates      | 4 (6.3%)   | 3 (9.1%)   | 1 (3.3%)   | 0.614   |
| Proton pump inhibitors | 7 (11.1%) | 4 (12.1%) | 3 (10%)    | 1       |
| Hormones             | 4 (6.3%)   | 1 (3%)     | 3 (10%)    | 0.343   |
| PDE5-Inhibitors      | 11 (17.5%) | 7 (21.2%)  | 4 (13.3%)  | 0.515   |
| Benzodiazepines      | 9 (14.3%)  | 6 (18.2%)  | 3 (10%)    | 0.479   |
slightly older (70.7±3.6 compared to 68.8±3.3) and apart from a higher rate of atrial fibrillation in the HBOT arm (4 patients 13.3% vs no patients 0%), there were no other significant differences between the two groups (Table 1).

**Cognitive function**

Results of the cognitive function evaluations are summarized in Tables 2, 3.

**Primary endpoint**

Both groups had similar global cognitive scores at baseline which was higher than the average score normalized to age and education level (>100). There was a significant group by time interaction in the primary endpoint of global cognitive function post HBOT compared to the control group (F=10.811, p=0.0017 with a net effect size of 0.849 (Tables 2, 3 and Figure 2).

**Secondary endpoints**

Both groups had similar cognitive scores in all domains measured by Neurotrax at baseline. The most striking improvements were in attention (net effect size=0.745, F=8.445, p=0.005) and information processing speed (net effect size=0.788, F=9.142, p=0.003) (Figure 2). Both overall memory domain score, the immediate and the delayed nonverbal memory scores were all improved post-HBOT compared to the control group (Tables 2, 3 and Figure 2). However, they were statistically insignificant following multi-comparisons corrections.

In the CANTAB battery, at baseline, the HBOT group had shorter response times. However, they were insignificant following multiple comparison corrections (Table 2). The HBOT group showed significant improvement in the set shifting task performance (a subset of executive function) (Tables 2, 3 and Figure 3). There was a significant reduction in median response time in both congruent (net effect size=−0.861, F=10.702, p<0.002) and incongruent trials (net effect size=−0.840, F=11.254, p=0.001) following HBOT (Tables 2, 3 and Figure 3). There was an increased performance in the visual memory task post-HBOT, which was statistically insignificant following multiple comparisons corrections. The results of covariate-adjusted (age and education) analyses were similar.

In the traditional paper and pencil tasks, at baseline, both groups showed similar cognitive functions in all tasks. Both verbal fluency (FAS semantic, net effect size=0.566, F=4.646, p=0.03) and verbal memory (RAVLT total, net effect size=0.603, F=5.439, p=0.02) improved in the HBOT group, compared to the control group. However, they were statically insignificant following multiple comparisons corrections (Table 2, 3). (See all cognitive results in Supplementary Tables 1, 2).

**Brain perfusion**

Ten subjects were excluded due to excessive head motion (>1mm or 1°) and ten subjects were excluded due to low AIF peak or wide AIF. A total of 20 subjects from the control group and 19 subjects from the HBOT group were included in the analysis.

There was an insignificant increase in whole brain CBF (p=0.054) and whole grey matter CBF (p=0.057) and no significant group by time interaction in whole brain, grey matter and white matter CBF (p>0.05) (Supplementary Table 3).

Voxel-based analysis revealed significant CBF increases in the HBOT group compared to the control group in the following regions: right superior medial frontal gyrus (BA 10), right and left supplementary motor area (BA 6), right middle frontal gyrus (BA 6), left middle frontal gyrus (BA 9), left superior frontal gyrus (BA 8) and the right superior parietal gyrus (BA 7) (Table 4 and Figure 4).

There were moderate correlations between cognitive score changes and these regional perfusion changes. The Neurotrax memory score change correlated to the left middle frontal gyrus CBF change (BA8), (r=0.379, p=0.023) and the attention score change correlated to the right middle frontal gyrus (BA6) (r=0.339, p=0.043). CANTAB set switching parameter changes correlated with the right superior frontal gyrus and supplementary motor area (BA6) (r=0.38-0.45, p<0.05, Supplementary Table 4). The RAVLT total score correlated with both the right superior medial frontal gyrus (r=0.393, p=0.016), right supplementary motor area (r=0.394, p=0.016) and the right superior parietal gyrus (r=0.380, p=0.002) (Table 4). The FAS semantic score change correlated with the right medial frontal gyrus (r=0.353, p=0.03) (Supplementary Table 4).

**Quality of life**

At baseline, there were no significant differences in all quality of life domains as calculated from the SF-36 questionnaire. All but the energy domain, had high
normal values (>75) in both groups. There was a significant increase in the HBOT group’s energy levels, compared to none in the control group (Supplementary Tables 5, 6).

Table 2. Neurocognitive performance changes.

|                             | Control Group | HBOT Group | 3 months P-value | Baseline Comparison P-value | Net Effect Size |
|-----------------------------|---------------|------------|------------------|-----------------------------|-----------------|
| **Neurotrax**               |               |            |                  |                             |                 |
| (N = 32)                    | (N = 29)      |            |                  |                             |                 |
| Primary Endpoint            |               |            |                  |                             |                 |
| Global cognitive score      | 102.19±8.51   | 103.00±8.27| 0.054            | 105.37±7.56                 | 110.58±6.76     |
| Memory                      | 105.20±7.54   | 105.53±7.10| 0.757            | 104.23±10.53                | 108.46±7.01     |
| Verbal - Immediate          | 104.77±13.65  | 109.15±8.72| 0.012            | 106.03±11.8                 | 106.67±10.56    |
| Verbal - Delayed            | 106.03±6.93   | 108.46±7.99| 0.339            | 100.57±12.3                 | 104.99±11.04    |
| Non-Verbal - Immediate      | 104.73±12.29  | 101.95±14.92| 0.202           | 107.89±15.4                 | 112.72±10.18    |
| Non-Verbal - Delayed        | 101.78±14.59  | 100.27±13.43| 0.513           | 103.82±12.34                | 109.46±10.18    |
| Executive Function          | 100.83±9.74   | 102.15±10.13| 0.207           | 109.17±8.92                 | 113.0±9.33      |
| Attention                   | 99.96±7.81    | 101.10±6.96| 0.247            | 102.89±9.66                 | 108.90±6.51     |
| Information Processing Speed| 104.42±12.21  | 104.02±13.85| 0.908           | 107.86±13.8                 | 116.02±14.0     |
| Motor Skills                | 100.29±11.43  | 99.90±10.98| 0.746            | 104.63±11.2                 | 107.79±9.03     |
| **CANTAB**                  |               |            |                  |                             |                 |
| (N = 33)                    | (N = 29)      |            |                  |                             |                 |
| Executive Function          |               |            |                  |                             |                 |
| ASTLCM(ms)                  | 882.51±110.85 | 885.98±111.91| 0.79            | 799.17±122.54               | 753.00±158.3    |
| ASTLCDM(ms)                 | 743.93±75.75  | 785.45±90.67| <0.000*         | 699.75±120.95               | 667.55±155.23   |
| ASTLCICM(ms)                | 961.48±121.99 | 963.37±128.53| 0.903           | 884.51±139.61               | 823.35±161.90   |
| ASTLCICMD(ms)               | 862.98±103.83 | 885.90±117.05| 0.133           | 800.5±131.42                | 745.41±148.57   |
| Pen and Paper               |               |            |                  |                             |                 |
| (N = 29)                    | (N = 28)      |            |                  |                             |                 |
| Executive function          |               |            |                  |                             |                 |
| RAVLT total Z-score         | 0.31±0.85     | 0.32±0.88   | 0.969            | 0.09±1.08                   | 0.61±0.94       |
| Verbal memory               |               |            |                  |                             |                 |
| Five points (percentile)    | 64.9±28.0     | 73.4±29.3  | 0.237            | 70.0±34.2                   | 88.3±16.8       |
| Verbal fluency              |               |            |                  |                             |                 |
| F-A-S Z-Score (Semantic)    | 0.52±1.04     | 0.36±1.04  | 0.568            | 0.02±0.80                   | 0.35±0.86       |

Baseline comparison p-value tests the null hypothesis of equal means of the two groups at the baseline using an unpaired t-test; 3 months comparison p-value tests the null hypothesis of equal means of each group pre-post intervention (HBOT/control respectively) using a paired t-test. Bold - P<0.05, *Satisfied Bonferroni corrections. Net effect size is the subtraction of Cohen’s D effect size of the control group from the HBOT group Cohen’s D effect size. Neurotrax scores are normalized to age, gender and education years. ASTLCM- The mean latency of response (from stimulus appearance to button press) on congruent trials. ASTLCMD - The median latency of response (from stimulus appearance to button press) on congruent trials.
ASTLCM - The mean latency of response (from stimulus appearance to button press) on incongruent trials.
ASTLICMD - The median latency of response (from stimulus appearance to button press) on incongruent trials.

Table 3. Neurocognitive function repeated measures analysis.

|                             | Main Effect of Group | Main Effect of Time | Interaction Effect (Group_by_Time) |
|-----------------------------|----------------------|---------------------|------------------------------------|
|                             | F        | p-value | F        | p-value | F        | p-value |
| **Neurotrax**               |          |         |          |         |          |         |
| **Primary Endpoint**        |          |         |          |         |          |         |
| Global Cognitive Score      | 7.171    | 0.009*  | 34.382   | <0.000* | 10.811   | 0.002*  |
| **Secondary Endpoints**     |          |         |          |         |          |         |
| Memory                      | 0.256    | 0.614   | 7.069    | 0.010*  | 5.186    | 0.026   |
| Verbal – Immediate          | 0.195    | 0.66    | 4.602    | 0.036   | 0.220    | 0.64    |
| Verbal - Delayed            | 4.61     | 0.036   | 5.732    | 0.02    | 1.216    | 0.274   |
| Non-verbal - Immediate      | 5.511    | 0.002*  | 0.33     | 0.567   | 4.512    | 0.037   |
| Non-verbal – Delayed        | 3.874    | 0.053   | 1.472    | 0.229   | 4.400    | 0.04    |
| Executive Function          | 17.321   | <0.000* | 9.346    | 0.003*  | 2.213    | 0.142   |
| Attention                   | 8.688    | 0.004*  | 18.2     | <0.000* | 8.445    | 0.005*  |
| Information Processing Speed| 5.634    | 0.021*  | 8.082    | 0.006*  | 9.142    | 0.003*  |
| Motor Skills                | 5.526    | 0.022*  | 1.781    | 0.187   | 2.964    | 0.09    |

**CANTAB**

|                             | Main Effect of Group | Main Effect of Time | Interaction Effect (Group_by_Time) |
|-----------------------------|----------------------|---------------------|------------------------------------|
|                             | F        | p-value | F        | p-value | F        | p-value |
| ASTLCM                      | 12.716   | 0.001*  | 3.408    | 0.07    | 4.458    | 0.039   |
| ASTLICMD                    | 8.980    | 0.004*  | 0.033    | 0.857   | 10.702   | 0.002*  |
| ASTLICM                     | 10.563   | 0.002*  | 5.488    | 0.023   | 6.146    | 0.016   |
| ASTLICMD                    | 11.183   | 0.001*  | 2.262    | 0.138   | 11.254   | 0.001*  |

**Pen and Paper**

|                             | Main Effect of Group | Main Effect of Time | Interaction Effect (Group_by_Time) |
|-----------------------------|----------------------|---------------------|------------------------------------|
|                             | F        | p-value | F        | p-value | F        | p-value |
| RAVLT Total Z-Score         | 0.059    | 0.809   | 6.876    | 0.011   | 5.439    | 0.023   |
| Five Points (Percentile)    | 2.400    | 0.127   | 16.641   | <0.000  | 1.778    | 0.188   |
| F-A-S Z-Score (Semantic)    | 1.449    | 0.234   | 1.233    | 0.271   | 4.646    | 0.035   |

Using a 2X2 repeated measures ANOVA model, the cognitive scores were compared between the 2 groups.

The first two columns present the between group effect. The 3rd and 4th columns report the time repeated effect (within group). The 5th and 6th columns report the group-by-time interaction;
Bold – P<0.05, *-Satisfied Bonferroni corrections;
Neurotrax scores are normalized to age, gender and education years.

**Safety**

Four participants (13.3%) experienced mild middle ear barotrauma (TEED 1-2) in the HBOT group compared to none (0%) in the control group. All events were treated conservatively and all participants completed their protocol. Fifteen participants (62% of those without intraocular lens implantation) had visual acuity changes in the HBOT group, compared to ten (37% of those without intraocular lens implantation). No changes were found in participants who had intraocular lens surgery prior to the study. In the HBOT group, nine patients (31.0%) had far sight acuity deterioration while six patients (20.6%) had improvement in their far sight acuity. Six patients (20.6%) had improved near sight acuity and three (10.3%) had near sight acuity deterioration. Four participants (16.7%) in the HBOT group, compared to nine (33.3%) in the control group had cataract level acceleration.

**DISCUSSION**

We found HBOT can induce significant enhancements in cognitive performance in healthy elderly. The main improved domains include attention, information processing speed and executive function (set shifting) in addition to global cognitive functions. Moreover, the HBOT group had a significantly enhanced brain perfusion in the superior and middle frontal gyri, supplementary motor area and superior parietal lobule.
Attention and information processing speed were significantly increased following HBOT compared to no change in the control group. In executive functions, the particular subset of set shifting improved significantly following HBOT compared to actual deterioration in the control group. These domains are known to gradually decline within the process of normal aging and play a crucial role in the daily functioning of the elderly [2]. Our results were in participants that had neither previous brain pathologies nor pathological cognitive declines (such as dementia or mild cognitive impairment) and had normal baseline cognitive scores. The memory domain, and mainly the non-verbal subdomain, improved in the HBOT group compared to no change in the control group. However, these changes did not reach corrected significance. We cannot rule out the possibility that in larger sample sizes, the memory domain effect would remain significant even after multi-comparisons corrections. Interestingly, the most significant cognitive changes were found in the computerized cognitive batteries and not in the traditional psychometric pen and paper tools. This may be due to the lack of proper alternative variations for the traditional tasks and low test-retest validity [20].

The HBOT net effect size of global cognitive score enhancement was 0.849 following 12 weeks HBOT sessions, substantially more than in other enhancement modalities. Colcombe et al. in a meta-analysis found that aerobic training in older adults improves mostly
Figure 2. NeuroTrax parameters significant changes. The NeuroTrax significant domains, shown in boxplots, with each line representing a patient flow from baseline to post intervention. The central mark indicates the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. Red symbols indicate outliers.

Executive function (task switching) followed by improvements in spatial and speed, and an overall improvement, with an effect size of $d=0.47$ [21]. Recently, a randomized controlled trial showed only the executive function moderately improving following aerobic training ($d=0.36$) with no significant changes in memory, language and verbal fluency domains ($d=0.12-0.15$) [8]. In contrast, our study shows that HBOT has a significant large net effect size of $0.84-0.86$ in the global cognitive score, task switching, as well as a significant net effect size in verbal fluency, attention, and information processing speed.

Previous studies have demonstrated a single oxygen exposure can enhance the cognitive function such as verbal function, visuospatial function through increased brain activation [22–26]. In a recent study, multitasking was significantly enhanced during hyperbaric oxygen exposure [27]. Yu et al. recently showed that five hyperbaric sessions enhance healthy young adults’ spatial memory, correlated with increased functional connectivity in the hippocampus, inferior frontal gyrus and lingual gyrus [28]. However, these changes were evaluated the day after the last hyperbaric session. In comparison, our intervention included 60 sessions within three months and to exclude transient effects of oxygen, all measurements were performed at least one week after the last hyperbaric session.

The current study HBOT protocol utilized the effects induced by repeated intermittent hyperoxic exposures, the so called hyperoxic hypoxic paradox [10]. These
Figure 3. CANTAB parameters significant changes. The set shifting parameters, shown in boxplots, with each line representing a patient flow from baseline to post intervention. The central mark indicates the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. Red symbols indicate outlier.

Table 4. Brain regions with significant perfusion increases.

| Anatomical location                              | BA | Coordinates | t-value |
|--------------------------------------------------|----|-------------|---------|
| Right superior medial frontal gyrus             | 6  | 10 30 64    | 4.63    |
| Right supplementary motor area                  | 6  | 8 24 70     | 3.72    |
| Left supplementary motor area                   | 6  | -14 0 78    | 3.92    |
| Right middle frontal gyrus                      | 6  | 38 12 60    | 4.56    |
| Right middle frontal gyrus                      | 6  | 38 4 82     | 3.8     |
| Left middle frontal gyrus                       | 9  | -38 22 52   | 4.52    |
| Left middle frontal gyrus                       | 8  | -26 32 56   | 4.13    |
| Right superior frontal gyrus                    | 10 | 18 68 8     | 4.04    |
| Right superior parietal gyrus                   | 7  | -48 18 38   | 4.41    |
| Right superior parietal gyrus                   | 7  | 24 -62 60   | 4.21    |

The tables report each brain region which was found significant in a time-by-group repeated measures ANOVA comparing the two groups. The results are showing in specific Montreal Neurological Institute (MNI) coordinates; X, sagittal, Y, coronal, Z, axial, refers to Montreal Neurological Institute. BA, Brodmann area.

All coordinates emerged at a threshold of $P < 0.05$, corrected; minimum cluster size: 25 (200 mm$^3$).

Intermittent hyperoxic exposures induce many of the physiological responses that occur during hypoxia [10]. HBOT induces the release of the transcription factors called hypoxic induced factor (HIF) and increases their stability and activity [11]. In turn, HIF-1α and HIF-2α modulate the release of the angiogenic factor vascular endothelial growth factor (VEGF) [29, 30]. VEGF is considered the master regulator of angiogenesis, and induces migration of progenitor endothelial cells from the bone marrow into the circulatory system, recruitment of endothelial cells from existing blood vessels and the differentiation into new formed blood vessels [31]. Importantly, the migration of these circulating angiogenic cells targets sites of ischemia where they promote vascular remodeling and stimulate angiogenesis [32]. As seen in ischemic brain injuries, neovascularization increases regional cerebral blood flow [14, 31, 33, 34]. We suggest that repeated oxygen level fluctuations may improve regional CBF and cognitive functions in healthy elderly.

Our protocol included 60 sessions of 100% oxygen at 2 ATA including 3 air breaks during each session in order to utilize the hyperoxic hypoxic paradox and minimize the risk for oxygen toxicity. However, the dose response curve related to the applied pressure, time
The significant improvement in CBF induced by HBOT in the current study population was in certain cortical regions. This finding is in agreement with the work by Martin et al. which demonstrated age-related functional decline is related to reduced perfusion in specific cortical locations rather and not the global CBF, but rather in the cortical regions that are the most sensitive for the age-related functional decline [4]. Recently, another study confirmed the selective age-related reductions in cortical perfusion [35]. Following HBOT, the increase in the CBF was in specific regions which participate in the following cognitive roles:

Superior medial frontal gyrus (SFG) (BA 10) - is thought to contribute to higher cognitive functions and has mostly been associated multitasking, attention, social cognition and episodic memory [36, 37].

Middle frontal gyrus (MFG) - has been proposed as a site of convergence of the dorsal and ventral attention networks. The MFG serves as a gateway to interrupt ongoing endogenous attentional processes in the dorsal attention network and reorient attention to an exogenous stimulus [38, 39].

Premotor cortex (BA6) - The premotor area and supplementary motor area (SMA) functions include motor sequencing and planning movements. It has been shown that area 6 participates in memory, attention and executive function as well as updating verbal function and updating spatial information [40].

Superior frontal gyrus (BA8) – traditionally, this area has been regarded as the frontal eye field. However, functional studies have shown significant participation of this area in executive function (including reasoning and planning), working memory and attention [41–43].

Superior parietal lobule (BA7) – also referred as the somatosensory association cortex (together with BA5), is believed to play a role in visuo-motor coordination and attention. In addition, it seems to participate in semantic categorization tasks and temporal context recognition [44].

Study limitations

The current study has several limitations and strengths to consider. First, the limited sample size has to be taken into account, possibly causing decreased sensitivity and false negative changes. However, the presence of significant changes following strict statistical analyses in a small group is indicative for the relatively high potency of the intervention. Second, the control group was a non-intervention rather than a sham-intervention. Although the outcome assessors were blinded, the participants were unblinded. Third, the duration of the effect is yet to be determined in long-term follow-ups. Nevertheless, several strengths should be stressed. The isolated HBOT effect was measured as both groups were monitored for any lifestyle changes (such as nutrition and exercise), medications or any other intervention that may have acted as possible confounders. Patients did not perform any cognitive training tasks during the trial, thereby excluding training effects. Both computerized cognitive batteries had alternate forms with test-retest validity as well as the brain perfusion sequence and analysis. Moreover, the improvements in the cognitive domains correlated with the significant changes in perfusion MRIs.

In summary, the study indicates that HBOT can induce cognitive enhancement in healthy aging populations. The main improvements include attention, information processing speed and executive functions, which are known to decline with normal aging. In correlation with the cognitive improvements, HBOT induced a significant brain perfusion increase in specific brain regions with high cognitive roles.

MATERIALS AND METHODS

Subjects

Seventy adults without pathological cognitive declines, aged 64 and older, who lived independently in good functional and cognitive status were enrolled. The study was performed between 2016-2020 in the Shamir (Assaf-Harofeh) Medical Center, Israel. Included patients did not have cardiac or cerebrovascular ischemia histories for the last year prior to inclusion. Exclusion criteria included: previous treatment with HBOT for any reason during the last three months, any history of malignancy during the last year, any pathological cognitive decline, severe chronic renal failure (GFR <30), uncontrolled diabetes mellitus (HbA1C>8, fasting glucose>200), immunosuppressants, MRI contraindications, active smoking and pulmonary diseases.

Included patients who were diagnosed with pathological cognitive decline based on their cognitive tests were...
excluded. Pathological cognitive decline was diagnosed by a certified neuropsychologist.

**Study design**

The study protocol was approved by Institutional Review Board of Shamir medical center, Israel. The study was performed as a randomized, prospective controlled clinical trial. After signing an informed consent, the subjects were assigned either to HBOT or control (no intervention) arms. Assessors were blinded to the participants’ intervention assignment. Measurement points were evaluated at baseline and 1-2 weeks after the HBOT or control period.

**Interventions**

The HBOT protocol was administrated in a multiplace Starmed-2700 chamber (HAUX, Germany). The protocol comprised of 60 daily sessions, 5 sessions per week within a three month period. Each session included breathing 100% oxygen by mask at 2ATA for 90 minutes with 5-minute air breaks every 20 minutes. Compression/decompression rates were 1 meter/minute. The control arm received no active intervention as a no-contact group. During the trial, neither lifestyle and diet changes, nor medications adjustments were allowed for either group.

**Cognitive measures**

Cognitive functions were assessed using two computerized batteries and one traditional paper-based battery, given by a certified neuropsychologist.

**NeuroTrax** computerized cognitive testing battery (NeuroTrax Corporation, Bellaire, TX). The NeuroTrax system and a detailed description of the tests included were detailed in previous publications [45–47] and are also available on the NeuroTrax website (http://www.neurotrax.com/).

In brief, the NeuroTrax tests evaluate multiple aspects of brain cognitive functions including: memory, executive function (EF), attention, information processing speed (IPS), motor skills (MS) visuospatial skills (VS) and verbal function (VF). Cognitive domain scores were normalized for age, gender and education-specific levels.

The participants completed validated alternate test forms of the NeuroTrax test battery at baseline and post-HBOT, to allow for iterative administrations with minimal learning effects. Test-retest reliability of the tests were found to be high in both normal and injured populations, without significant learning effects except in the VF and VS domains that were not evaluated in the current study [48, 49].

**CANTAB** computerized cognitive tests (Cambridge cognition, England) [50]. CANTAB is a semiautomated test battery which can be administered on a handheld tablet. The battery included: attention switching tasks (AST) for executive function and set shifting testing, pair associates learning (PAL) for evaluating visual memory and new learning, reaction time (RTI), rapid visual information processing (RVP) for assessing sustained attention, spatial span (SSP) for assessing visuospatial working memory and spatial working memory (SWM) [51, 52]. To combine accuracy and reaction time, the inverse efficiency score (IES) was calculated by the following formula:

\[
IES = \frac{\text{response time}}{1 - \text{percentage of errors}}
\]

Notably, the patients were given different test versions of the CANTAB test battery at baseline and after the control/HBOT period, to allow repeated administrations with minimal learning effects. The current version of CANTAB has no population norms for either parameter.

**Traditional paper and pencil based** neuropsychological tests included: the Rey-Osterrieth complex figure test (ROCFT), a popular measure of visuocostructive skills and visual memory [53]; the Rey auditory verbal learning test (RAVLT), a neuropsychological assessment designed to evaluate verbal memory in patients [54]; the digit symbol substitution test (DSST) offers high sensitivity to detect overall cognitive impairment rather than a specific domain [55]; a digit-span (DS) task, used to measure working memory’s number storage capacity [56]; the five points test (5PT) is a structured and standardized test that assesses figural fluency functions which are associated with executive functioning [57]; the trails making test (TMT), a widely used test that assesses organized visual search, planning, attention, set shifting, cognitive flexibility, and divided attention, all capacities thought to be executive in nature [58]; the FAS test, which measures phonemic word fluency, which is a type of verbal fluency [59]; the bells test, a cancellation test, which permits qualitative and quantitative evaluation of visual neglect [60]. Scores were normalized to age, gender and education as suggested in the manuals and presented as Z-scores. In case of diagnosed pathological cognitive decline using both the cognitive scores and MMSE, the patients were excluded from the study.

**Brain MRIs**
MRI scans were performed on a MAGNETOM Skyra 3T scanner, configured with 20-channel receiver head coils (Siemens Healthcare, Erlangen, Germany). The MRI protocol included dynamic susceptibility contrast (DSC), and post-contrast high-resolution MPRAGE 3D T1-weighted images. MRI sequences parameters:

**DSC:** Fifty T2*-weighted gradient-echo echo planar imaging (EPI) volumes were acquired, two repetitions before a bolus injection of gadolinium-DTPA (Gd-DTPA, 0.2 ml/kg, administered at 5 ml/sec), 48 repetitions after injection of Gd-DTPA. Sequence parameters: TR: 2,300 ms, TE: 40ms, flip angle: 30°, voxel size: 1.8 x 1.8, matrix: 128x128, number of slices: 25, and slice thickness = 3.9 mm.

**MPRAGE 3D:** was acquired in sagittal orientation with 0.9 mm isotropic resolution. Sequence parameters: TR: 2,000 ms, TE: 2.41 ms, flip angle: 8°, TI: 928 ms, FOV: 245 x 245, and 192 contiguous slices.

**DSC-MRI analysis**

The preprocessing of the perfusion MRI data was preformed using the SPM software (version 12, UCL, London, UK) and included motion correction, and co-registration with MPRAGE T1 images. Individual gray matter (GM) and white matter (WM) segmentation of T1 anatomy was also performed to extract mean perfusion values. Whole-brain quantitative perfusion analysis was performed as described in previous studies [61, 62]. Detailed description is found in the supplementary material (SI-1). Briefly, MR signal intensity was converted to Gd concentrations, AIF was determined automatically, fitted to the gamma variate function and deconvolved on a voxel-by-voxel basis to calculate the CBF, CBV, and MTT maps. Following normalization to MNI space, WM and GM masking and smoothing using a 6 mm full-width at half-maximum Gaussian kernel, statistical analysis was performed on the normalized CBF maps, using the voxel-based method.

**Quality of life measures**

The RAND health status survey, short form-36 (SF-36) was used to assess quality of life. SF-36 is a self-report measure that evaluates physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional health, general mental health, social functioning, energy/fatigue, and general health perception [63–65]. Each scale generates a score from 0 to 100, with a high score indicating better health and less body pain.

**Safety**

Participants were monitored for adverse events including: barotraumas (either ear or sinuses), oxygen toxicity (pulmonary and central nervous system). Participants were examined by a certified blinded ophthalmologist before and after the control/HBOT term to monitor visual acuity and cataracts.

**Statistical analysis**

Continuous data were expressed as means ± standard-deviation. The normal distribution for all variables was tested using the Kolmogorov-Smirnov test. unpaired and paired t-tests were performed to compare variables between and within the two groups. Net effect sizes were evaluated using Cohen’s d method.

Continuous parameters correlations were performed using Pearson and Spearman’s as appropriate.

Categorical data is expressed in numbers and percentages and compared by chi-square tests. Univariate analyses were performed using Chi-Square/Fisher’s exact test to identify significant variables (P<0.05).

To evaluate HBOT’s effects on cognitive scores, a within-subject repeated measures ANOVA model was used to test the main interaction effect between time and group. The false discovery rate (FDR) method was used for multiple comparisons correction. In addition, covariate-adjusted effects were examined, with covariates of age, sex and years of education.

To evaluate HBOT’s effects on CBF, statistical analysis was performed on the normalized CBF maps, using the voxel-based method implemented in SPM12 (Wellcome Trust Centre for Neuroimaging, London, England). A within-subject repeated measure ANOVA model was used to test the main interaction effect between time and group, using the SPM factorial model. The statistical significance level was set to a voxel-wise P-value of 0.05 corrected for multiple comparisons using the sequential Hochberg correction [66], with a minimum cluster size of 25 (200 mm3) contiguous significant voxels. CBF values in each cluster were extracted and averaged.

Statistical significance threshold was set to 0.05. Data were statistically analyzed using MatLAB 2018b (Mathworks, Natick, MA).

**Sample size**
Based on previous studies on cognitive improvements following HBOT, assuming a five-point improvement in the global cognitive score in NeuroTrax following HBOT, compared to two points in the control group, with a four point standard deviation of the change, with a power of 80% and an alpha of 5%, 29 participants would be required in each arm. Adding a 15% dropout rate would require 70 patients in total.

**AUTHOR CONTRIBUTIONS**

All authors contributed substantially to the preparation of this manuscript. HA, ES were responsible for protocol design. HA, ZY, BY, ES, DKM were responsible for patients’ recruitment. HA, DGM, SG, BGR, DG, HY, AHR, FG, LE, PN, DK, FM, TS, ZY, BY were responsible for data acquisition. HA, CM, SE, and ES were responsible for data analysis. All authors interpreted the data. HA, CM, ES and ES wrote the manuscript. All authors revised and finalized the manuscript.

**ACKNOWLEDGMENTS**

We would like to thank Dr. Mechael Kanovsky for his editing of this manuscript.

**CONFLICTS OF INTEREST**

AH, ES, RBG, SG, BY, ZY work for AVIV Scientific LTD. ES is a shareholder at AVIV Scientific LTD.

**FUNDING**

The study was funded by a research grant from the Sagol Network for Neuroscience established by Mr. Sami Sagol.

**REFERENCES**

1. Cedres N, Machado A, Molina Y, Diaz-Galvan P, Hernández-Cabrera JA, Barroso J, Westman E, Ferreira D. Subjective cognitive decline below and above the age of 60: a multivariate study on neuroimaging, cognitive, clinical, and demographic measures. J Alzheimers Dis. 2019; 68:295–309. https://doi.org/10.3233/JAD-180720 PMID:30741680

2. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013; 29:737–52. https://doi.org/10.1016/j.cger.2013.07.002 PMID:24094294

3. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011; 12:723–38. https://doi.org/10.1038/nrnn3114 PMID:22048062

4. Martin AJ, Friston KJ, Colebatch JG, Frackowiak RS. Decreases in regional cerebral blood flow with normal aging. J Cereb Blood Flow Metab. 1991; 11:684–89. https://doi.org/10.1038/jcbfm.1991.121 PMID:2050757

5. Wang L, Du Y, Wang K, Xu G, Luo S, He G. Chronic cerebral hypoperfusion induces memory deficits and facilitates Aβ generation in C57BL/6J mice. Exp Neurol. 2016; 283:353–64. https://doi.org/10.1016/j.expneurol.2016.07.006 PMID:27421879

6. Berman RF, Goldman H, Altman HJ. Age-related changes in regional cerebral blood flow and behavior in sprague-dawley rats. Neurobiol Aging. 1988; 9:691–96. https://doi.org/10.1016/s0197-4580(88)80134-9 PMID:3062475

7. Klimova B, Valis M, Kuca K. Cognitive decline in normal aging and its prevention: a review on non-pharmacological lifestyle strategies. Clin Interv Aging. 2017; 12:903–10. https://doi.org/10.2147/CIA.S132963 PMID:28579767

8. Blumenthal JA, Smith PJ, Mabe S, Hinderliter A, Lin PH, Liao L, Welsh-Bohmer KA, Browndyke JN, Kraus WE, Doraissamy PM, Burke JR, Sherwood A. Lifestyle and neurocognition in older adults with cognitive impairments: a randomized trial. Neurology. 2019; 92:e212–23. https://doi.org/10.1212/WNL.0000000000006784 PMID:30568005

9. Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018; 168:39–51. https://doi.org/10.7326/M17-1529 PMID:29255847

10. Cimino F, Balestra C, Gemonpré P, De Bels D, Tillmans F, Saija A, Speciale A, Virgili F. Pulsed high oxygen induces a hypoxic-like response in human umbilical endothelial cells and in humans. J Appl Physiol (1985). 2012; 113:1684–89. https://doi.org/10.1152/japplphysiol.00922.2012 PMID:23042909

11. Sunkari VG, Lind F, Botusan IR, Kashif A, Liu ZJ, Ylä-Herttuala S, Brismar K, Velazquez O, Catrina SB. Hyperbaric oxygen therapy activates hypoxia-inducible factor 1 (HIF-1), which contributes to improved wound healing in diabetic mice. Wound Repair Regen. 2015; 23:98–103. https://doi.org/10.1111/wrr.12253 PMID:25532619
12. Milovanova TN, Bhopale VM, Sorokina EM, Moore JS, Hunt TK, Hauer-Jensen M, Velazquez OC, Thom SR. Hyperbaric oxygen stimulates vasculogenic stem cell growth and differentiation in vivo. J Appl Physiol (1985). 2009; 106:711–28. https://doi.org/10.1152/japplphysiol.91054.2008 PMID:19023021

13. Yang Y, Wei H, Zhou X, Zhang F, Wang C. Hyperbaric oxygen promotes neural stem cell proliferation by activating vascular endothelial growth factor/extracellular signal-regulated kinase signaling after traumatic brain injury. Neuroreport. 2017; 28:1232–1238. https://doi.org/10.1097/WNR.0000000000000901 PMID:28953090

14. Liman TG, Endres M. New vessels after stroke: postischemic neovascularization and regeneration. Cerebrovasc Dis. 2012; 33:492–99. https://doi.org/10.1159/000337155 PMID:22517438

15. Efrati S, Fishlev G, Bechor Y, Volkov O, Bergan J, Kliakhandler K, Kamiager I, Gal N, Friedman M, Ben-Jacob E, Golan H. Hyperbaric oxygen induces late neuroplasticity in post stroke patients—randomized, prospective trial. PLoS One. 2013; 8:e53716. https://doi.org/10.1371/journal.pone.0053716 PMID:2335971

16. Boussi-Gross R, Golan H, Fishlev G, Bechor Y, Volkov O, Bergan J, Friedman M, Hoofien D, Shlamkovitch N, Ben-Jacob E, Efrati S. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury - randomized prospective trial. PLoS One. 2013; 8:e79995. https://doi.org/10.1371/journal.pone.0079995 PMID:24260334

17. Boussi-Gross R, Golan H, Volkov O, Bechor Y, Hoofien D, Beeri MS, Ben-Jacob E, Efrati S. Improvement of memory impairments in poststroke patients by hyperbaric oxygen therapy. Neuropsychology. 2015; 29:610–21. https://doi.org/10.1037/neu0000149 PMID:25384125

18. Hadanny A, Golan H, Fishlev G, Bechor Y, Volkov O, Suzin G, Ben-Jacob E, Efrati S. Hyperbaric oxygen can induce neuroplasticity and improve cognitive functions of patients suffering from anoxic brain damage. Restor Neurol Neurosci. 2015; 33:471–86. https://doi.org/10.3233/RNN-150517 PMID:26409406

19. Hadanny A, Abbott S, Suzin G, Bechor Y, Efrati S. Effect of hyperbaric oxygen therapy on chronic neurocognitive deficits of post-traumatic brain injury patients: retrospective analysis. BMJ Open. 2018; 8:e023387. https://doi.org/10.1136/bmjopen-2018-023387 PMID:30269074

20. Björngrim S, van den Hurk W, Betancort M, Machado A, Lindau M. Comparing traditional and digitized cognitive tests used in standard clinical evaluation - a study of the digital application minnemera. Front Psychol. 2019; 10:2327. https://doi.org/10.3389/fpsyg.2019.02327 PMID:31681117

21. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci. 2003; 14:125–30. https://doi.org/10.10111/1467-9280.t01-1-01430 PMID:12661673

22. Chung SC, Tack GR, Lee B, Eom GM, Lee SY, Sohn JH. The effect of 30% oxygen on visuospatial performance and brain activation: an fMRI study. Brain Cogn. 2004; 56:279–85. https://doi.org/10.1016/j.bandc.2004.07.005 PMID:15522765

23. Chung SC, Sohn JH, Lee B, Tack GR, Yi JH, You JH, Jun JH, Sparacio R. The effect of transient increase in oxygen level on brain activation and verbal performance. Int J Psychophysiol. 2006; 62:103–08. https://doi.org/10.1016/j.ijpsycho.2006.02.006 PMID:16678926

24. Sohn JH, Chung SC, Jang EH. 30% oxygen inhalation enhances cognitive performance through robust activation in the brain. J Physiol Anthropol Appl Human Sci. 2005; 24:51–53. https://doi.org/10.2114/jpa.24.51 PMID:15684544

25. Scholey AB, Moss MC, Neave N, Wesnes K. Cognitive performance, hyperoxia, and heart rate following oxygen administration in healthy young adults. Physiol Behav. 1999; 67:783–89. https://doi.org/10.1016/s0031-9384(99)00183-3 PMID:10604851

26. Scholey AB, Moss MC, Wesnes K. Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory. Psychopharmacology (Berl). 1998; 140:123–26. https://doi.org/10.1007/s002130050748 PMID:9862412

27. Vadas D, Kalichman L, Hadanny A, Efrati S. Hyperbaric oxygen environment can enhance brain activity and multitasking performance. Front Integr Neurosci. 2017; 11:25. https://doi.org/10.3389/fnint.2017.00025 PMID:29021747

28. Yu R, Wang B, Li S, Wang J, Zhou F, Chu S, He X, Wen X, Ni X, Liu L, Xie Q, Huang R. Cognitive enhancement of
healthy young adults with hyperbaric oxygen: a preliminary resting-state fMRI study. Clin Neurophysiol. 2015; 126:2058–67. https://doi.org/10.1016/j.clinph.2015.01.010 PMID:25703942

29. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16:4604–13. https://doi.org/10.1128/mcb.16.9.4604 PMID:8756616

30. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5’ enhancer. Circ Res. 1995; 77:638–43. https://doi.org/10.1161/01.res.77.3.638 PMID:7641334

31. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011; 2:1117–33. https://doi.org/10.1077/1947601911423654 PMID:2286203

32. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18:3964–72. https://doi.org/10.1002/10.1002/emboj.18.14.3964 PMID:10406801

33. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002; 8:607–12. https://doi.org/10.1038/nm0602-607 PMID:12042812

34. Ergul A, Abdelsaid M, Fouda AY, Fagan SC. Cerebral neovascularization in diabetes: implications for stroke recovery and beyond. J Cereb Blood Flow Metab. 2014; 34:553–63. https://doi.org/10.1038/jcbfm.2014.18 PMID:24496174

35. Chen JJ, Rosas HD, Salat DH. Age-associated reductions in cerebral blood flow are independent from regional atrophy. Neuroimage. 2011; 55:468–78. https://doi.org/10.1016/j.neuroimage.2010.12.032 PMID:21167947

36. Burgess PW, Dumontheil I, Gilbert SJ. The gateway hypothesis of rostral prefrontal cortex (area 10) function. Trends Cogn Sci. 2007; 11:290–98. https://doi.org/10.1016/j.tics.2007.05.004 PMID:17548231

37. Gilbert SJ, Spengler S, Simons JS, Steele JD, Lawrie SM, Frith CD, Burgess PW. Functional specialization within rostral prefrontal cortex (area 10): a meta-analysis. J Cogn Neurosci. 2006; 18:932–48. https://doi.org/10.1162/jocn.2006.18.6.932 PMID:16839301

38. Mayer AR, Dorflinger JM, Rao SM, Seidenberg M. Neural networks underlying endogenous and exogenous visual-spatial orienting. Neuroimage. 2004; 23:534–41. https://doi.org/10.1016/j.neuroimage.2004.06.027 PMID:15488402

39. Japee S, Holiday K, Satyshur MD, Mukai I, Ungerleider LG. A role of right middle frontal gyrus in reorienting of attention: a case study. Front Syst Neurosci. 2015; 9:23. https://doi.org/10.3389/fnsys.2015.00023 PMID:25784862

40. Tanaka S, Honda M, Sadato N. Modality-specific cognitive function of medial and lateral human brodmann area 6. J Neurosci. 2005; 25:496–501. https://doi.org/10.1523/JNEUROSCI.4324-04.2005 PMID:15647494

41. Volz KG, Schubotz RI, von Cramon DY. Why am I unsure? internal and external attributions of uncertainty dissociated by fMRI. Neuroimage. 2004; 21:848–57. https://doi.org/10.1016/j.neuroimage.2003.10.028 PMID:15006651

42. Janata P. The neural architecture of music-evoked autobiographical memories. Cereb Cortex. 2009; 19:2579–94. https://doi.org/10.1093/cercor/bhp008 PMID:19240137

43. du Boisgueheneuc F, Levy R, Volle E, Seassau M, Duffau H, Kinkingnehun S, Samson Y, Zhang S, Dubois B. Functions of the left superior frontal gyrus in humans: a lesion study. Brain. 2006; 129:3315–28. https://doi.org/10.1093/brain/awl244 PMID:16984899

44. Haines DE. (2012). Fundamental Neuroscience for Basic and Clinical Applications.

45. Zur D, Naftaliev E, Kesler A. Evidence of multidomain mild cognitive impairment in idiopathic intracranial hypertension. J Neuroophthalmol. 2015; 35:26–30. https://doi.org/10.1097/WNO.0000000000000199 PMID:25383589

46. Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, Bercovich E, Polliack M, Doniger GM, Stern Y, Khilkevich O, Menascu S, Hararai G, Gurevich M, Barak Y. Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS One. 2013; 8:e71058.
47. Thaler A, Mirelman A, Gurevich T, Simon E, Orr-Urtreger A, Marder K, Bressman S, Giladi N, and LRRK2 Ashkenazi Jewish Consortium. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology. 2012; 79:1027–32. https://doi.org/10.1212/WNL.0b013e3182684646 PMID:22914834

48. Dwolatzky T, Whitehead V, Doniger GM, Simon ES, Schweiger A, Jaffe D, Chertkow H. Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatr. 2003; 3:4. https://doi.org/10.1186/1471-2318-3-4 PMID:14594456

49. L. Melton J. (2005). Psychometric Evaluation of the Mindstreams Neuropsychological Screening Tool.

50. Zygouris S, Tsolaki M. Computerized cognitive testing for older adults: a review. Am J Alzheimers Dis Other Demen. 2015; 30:13–28. https://doi.org/10.1080/1533317514522852 PMID:24526761

51. Klekociuk SZ, Summers JJ, Vickers JC, Summers MJ. Reducing false positive diagnoses in mild cognitive impairment: the importance of comprehensive neuropsychological assessment. Eur J Neurol. 2014; 21:1330–36. https://doi.org/10.1111/ene.12488 PMID:24943259

52. Saunders NL, Summers MJ. Attention and working memory deficits in mild cognitive impairment. J Clin Exp Neuropsychol. 2010; 32:350–57. https://doi.org/10.1080/13803390903042379 PMID:19787522

53. Lu PH, Boone KB, Cozolino L, Mitchell C. Effectiveness of the rey-osterrieth complex figure test and the meyers and meyers recognition trial in the detection of suspect effort. Clin Neuropsychol. 2003; 17:426–40. https://doi.org/10.1076/clin.17.3.426.18083 PMID:14704893

54. Vakil E, Blachstein H. Rey AVLT: Developmental norms for adults and the sensitivity of different memory measures to age. The Clinical Neuropsychologist. 1997; 11:356–69. https://doi.org/10.1080/13854049708400464

55. Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018; 38:513–19. https://doi.org/10.1097/JCP.0000000000000941 PMID:30124583

56. Humpstone HJ. Memory span tests. Psychol Clin. 1919; 12:196–200. PMID:28909279

57. Tucha L, Aschenbrenner S, Koerts J, Lange KW. The five-point test: reliability, validity and normative data for children and adults. PLoS One. 2012; 7:e46080. https://doi.org/10.1371/journal.pone.0046080 PMID:23029395

58. Rabin LA, Barr WB, Burton LA. Assessment practices of clinical neuropsychologists in the united states and Canada: a survey of INS, NAN, and APA division 40 members. Arch Clin Neuropsychol. 2005; 20:33–65. https://doi.org/10.1016/j.acn.2004.02.005 PMID:15620813

59. Barry D, Bates ME, Labouvie E. FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study. Appl Neuropsychol. 2008; 15:97–106. https://doi.org/10.1080/09084280802083863 PMID:18568601

60. Paiva SC, Viapiana VF, Cardoso CO, Fonseca RP. Bells test: are there differences in performance between adult groups aged 40-59 and 60-75? Dement Neuropsychol. 2017; 11:40–47. https://doi.org/10.1590/1980-57642016dn11-010007 PMID:29213492

61. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis. Magn Reson Med. 1996; 36:715–25. https://doi.org/10.1002/mrm.1910360510 PMID:8916022

62. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med. 1996; 36:726–36. https://doi.org/10.1002/mrm.1910360511 PMID:8916023

63. Russo J, Trujillo CA, Wingerson D, Decker K, Ries R, Wetzler H, Roy-Byrne P. The MOS 36-item short form health survey: reliability, validity, and preliminary findings in schizophrenic outpatients. Med Care. 1998; 36:752–56. https://doi.org/10.1097/00005650-199805000-00015 PMID:9596066

64. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32:40–66. https://doi.org/10.1097/00005650-199401000-00004
65. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31:247–63. https://doi.org/10.1097/00005650-199303000-00006
PMID:8450681

66. Hochberg Y. A Sharper Bonferroni Procedure for Multiple Tests of Significance. Biometrika. 1988; 75:800–2. https://doi.org/10.1093/biomet/75.4.800
Supplementary Methods

SI-1: MRI analysis

DSC analysis steps:

1. Conversion of signal intensity to concentration of Gd-DTPA with respect to time:

\[ C_m(t) = -K \ln \left( \frac{S(t)}{S_0} \right) \]

where \( C_m(t) \) is the measured concentration of Gd-DTPA with respect to time, \( K \) is a proportionality constant that is inversely proportional to the TE and depends on the MR scanner, \( S(t) \) is the MRI signal intensity with respect to time, and so is the baseline MRI signal before the presence of Gd-DTPA and after a steady-state magnetization has been achieved [3].

2. Arterial input function: the AIF was measured automatically, using the following algorithm:

   a. The volume with maximum \( C_m(t) \) intensity was identified (10th-13th volume). Only voxels with maximum intensity in this volume were identified as AIF candidates.
   
   b. Only voxels with maximum intensity higher than the 96th percentile and lower than the 99.9th percentile were included.
   
   c. Only voxels with a shape of sharp increase and sharp decrease were included.
   
   d. The AIF voxel candidates were fitted to the gamma variate function using the following equation [3]. Goodness of fit was evaluated and only voxels with \( R^2 > 0.96 \) were included.

\[ AIF_{fit}(t) \text{or } C_{fit}(t) = -K(x - \Delta)^\alpha e^{-\frac{x-\Delta}{\beta}} F_{step}(x - \Delta) \]

where \( \alpha \) and \( B \) are gamma variate parameters, and \( F_{step} \) is a step function defined by:

\[ F_{step} = \begin{cases} 1 & \text{for } (x - \Delta) \geq 0 \\ 0 & \text{for } (x - \Delta) < 0 \end{cases} \]

4. SVD deconvolution: The fitted AIF was used to calculate \( C(t) \) (the tissue response to an instantaneous arterial bolus) using SVD deconvolutions was done by Ostergaard et al. (1996). In short, the values for the AIF and \( C_m(t) \) curves can be written in vector notation as \( C = AIF^{-1} \cdot C_m \), where \( C \) represents the matrix of the deconvolved \( C(t) \) curve. This equation can be solved using the SVD technique, whereby the matrix AIF is decomposed into three matrices \( AIF = U \cdot W \cdot VT \). The inverse of AIF can be calculated as \( AIF^{-1} = V \cdot [\text{diag}(1/wj)] \cdot UT \), where \( [\text{diag}(1/wj)] \) represents the reciprocals of the diagonal elements of \( W \). When calculating \( AIF^{-1} \), problems arise when \( W \) contains singular values (i.e., \( wj = 0 \) or is close to 0) and will cause the curve \( C(t) \) to oscillate. Therefore, we used a cutoff threshold of 10% [1].

5. Calculation of CBV was performed based on the fitted \( C_m(t) \) and AIF:

\[ CBV = \frac{k}{\rho} \int_{0}^{\infty} \frac{C_m(t)dt}{AIF(t)dt} \]

where \( k = (1 - HCTLV)/(1 - HCTSV) \) corrects for the fact that the hematocrit in large vessels (HCTLV was set to 0.45) is larger than the hematocrit of small vessels (HCTSV was set to 0.25) (1) and \( \rho \) is the density of brain tissue (1.04 g/ml) [3].

6. Calculation of CBF was performed using the following equation:

\[ \frac{CBV}{CBF} = \int_{0}^{\infty} \frac{C(t)dt}{C_{max}} \]

where \( C(t) \) is the concentration of Gd-DTPA in a tissue region and \( C_{max} \) is the maximum of this curve [3].
7. MTT was calculated [2]:

\[ MTT = \frac{CBV}{CBF} \]

8. Normalization of the CBF: Since the amount of injection was not uniform between scans, the CBF was normalized using a factor of 1.9 divided by the AIF peak value.

Supplementary References

1. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magn Reson Med. 1996; 36:726–36. https://doi.org/10.1002/mrm.1910360511 PMID:8916023

2. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med. 1996; 36:715–25. https://doi.org/10.1002/mrm.1910360510 PMID:8916022

3. Smith AM, Grandin CB, Duprez T, Mataigne F, Cosnard G. Whole brain quantitative CBF, CBV, and MTT measurements using MRI bolus tracking: implementation and application to data acquired from hyperacute stroke patients. J Magn Reson Imaging. 2000; 12:400–10. https://doi.org/10.1002/1522-2586(200009)12:3<400::aid-jmri5>3.0.co;2-c PMID:10992307
Supplementary Tables

Please browse Full Text version to see the data of Supplementary Table 1.

Supplementary Table 2. Neurocognitive function repeated measures analysis.

|                | Main Effect of Group | Main Effect of Time | Interaction Effect (Group by Time) |
|----------------|----------------------|---------------------|------------------------------------|
| **Neurotrax**  |                      |                     |                                    |
| **Primary Endpoint** |                      |                     |                                    |
| Global Cognitive Score | 7.171                | 0.009*              | 34.382                             | 0.010*            |
| **Secondary Endpoints** |                      |                     |                                    |
| Memory          | 0.256                | 0.614               | 7.069                              | 0.002*            |
| Verbal – Immediate | 0.195                | 0.66                | 4.602                              | 0.036             |
| Verbal - Delayed | 4.61                 | 0.036               | 5.732                              | 0.02              |
| Non-verbal - Immediate | 5.511               | 0.002*              | 0.33                               | 0.567             |
| Non-verbal – Delayed | 3.874               | 0.053               | 1.472                              | 0.229             |
| **Executive Function** | 17.321               | <0.000*             | 9.346                              | 0.003*            |
| Attention       | 8.688                | 0.004*              | 18.2                               | <0.000*           |
| Information Processing Speed | 5.634              | 0.021*              | 8.082                              | 0.006*            |
| Motor Skills    | 5.526                | 0.022*              | 1.781                              | 0.187             |
| **CANTAB**      |                      |                     |                                    |
| ASTLCM          | 12.716               | 0.001*              | 3.408                              | 0.07              |
| ASTLCMD         | 8.980                | 0.004*              | 0.033                              | 0.857             |
| ASTLICM         | 10.563               | 0.002*              | 5.488                              | 0.023             |
| ASTLICMD        | 11.183               | 0.001*              | 2.262                              | 0.138             |
| ASTLDM          | 14.911               | <0.000*             | 0.98                               | 0.326             |
| ASTLM           | 11.98                | 0.001*              | 4.855                              | 0.031             |
| IES             | 9.217                | 0.003*              | 3.023                              | 0.087             |
| PALTEA          | 0.124                | 0.726               | 3.022                              | 0.08              |
| PALTEA8         | 0.023                | 0.88                | 1.208                              | 0.276             |
| RTIFMRT         | 10.019               | 0.002*              | 0.077                              | 0.782             |
| RTIFMDRT        | 11.321               | 0.001*              | 0.029                              | 0.864             |
| RVPM6DL         | 5.125                | 0.027               | 0.744                              | 0.392             |
| SSPFSF          | 0.038                | 0.847               | 5.441                              | 0.023             |
| SSPRSL          | <0.0001             | 0.989               | 0.388                              | 0.536             |
| SWMBE           | 1.156                | 0.287               | 2.293                              | 0.136             |
| **Pen and Paper** |                      |                     |                                    |
| ROCFT Z-Score (immediate) | 2.326            | 0.133               | 0.22                               | 0.641             | 0     | 0.995 |
| ROCFT Z-Score (delayed) | 1.496               | 0.226               | 14.503                             | <0.000            | 0.009 | 0.925 |
| Digit symbol substitution test(Z) | 1.451          | 0.234               | 17.317                             | <0.000            | 3.598 | 0.064 |
| Digit Span (Z-score) | 0.000              | 0.986               | 0.537                              | 0.467             | 2.872 | 0.097 |
| RAVLT total (Z-score) | 0.059               | 0.809               | 6.876                              | 0.011             | 5.439 | 0.023 |
| Five Points (percentile) | 2.400           | 0.127               | 16.641                             | <0.000            | 1.778 | 0.188 |
| Trials B (Z-score) | 0.191               | 0.664               | 3.694                              | 0.06              | 0.282 | 0.597 |
| F-A-S Z-score (Semantic) | 1.449            | 0.234               | 1.233                              | 0.271             | 4.646 | 0.035 |

Using a 2X2 repeated measures ANOVA model, the cognitive scores were compared between the 2 groups. The first two columns present the between group effect. The 3rd and 4th columns report the time repeated effect (within group). The 5th and 6th columns report the group-by-time interaction;

Bold – P<0.05, *-Satisfied Bonferroni corrections. Neurotrax scores are normalized to age, gender and education years.
### Supplementary Table 3. Global cerebral blood flow changes.

|                      | Control Group (N=19) | HBOT Group (N=20) | 3 months | Post-HBOT | 3 months | Group by time |
|----------------------|----------------------|-------------------|-----------|-----------|-----------|---------------|
|                      | Baseline             | Control           | P-value   | Baseline  | Post-HBOT | P-value       | P-value       |
| Whole Brain          | 41.34±6.22           | 41.55±6.78        | 0.88      | 47.13±7.69| 50.22±7.26| 0.054         | 0.014         | 0.180         |
| Grey Matter          | 47.79±8.84           | 47.93±9.89        | 0.94      | 58.20±9.43| 61.92±8.22| 0.057         | 0.001         | 0.170         |
| White Matter         | 28.40±7.35           | 28.57±7.17        | 0.88      | 29.12±6.37| 30.67±4.93| 0.198         | 0.747         | 0.472         |

### Supplementary Table 4. Significant correlations between cognitive changes and perfusion changes.

| Area                           | BA | Battery | Test             | Parameter   | R     | P-Value |
|-------------------------------|----|---------|------------------|-------------|-------|---------|
| Right superior medial frontal gyrus | 6  | CANTAB  | Set shifting     | ASTLCM      | -0.343| 0.03    |
| Right superior medial frontal gyrus | 6  | CANTAB  | Set shifting     | ASTLCD      | -0.384| 0.01    |
| Right superior medial frontal gyrus | 6  | CANTAB  | Set shifting     | ASTLM       | -0.455| 0.004   |
| Right superior medial frontal gyrus | 6  | CANTAB  | Set shifting     | ASTLICM     | -0.41 | 0.01    |
| Right superior medial frontal gyrus | 6  | CANTAB  | Set shifting     | ASTLICMD    | -0.473| 0.003   |
| Right superior medial frontal gyrus | 6  | CANTAB  | Set shifting     | ASTLM       | -0.386| 0.01    |
| Right supplementary motor area | 6  | CANTAB  | Set Shifting     | ASTLICMD    | -0.323| 0.048   |
| Right supplementary motor area | 6  | CANTAB  | Set Shifting     | ASTLDM      | -0.363| 0.025   |
| Right supplementary motor area | 6  | CANTAB  | Set Shifting     | ASTLICMD    | -0.379| 0.02    |
| Left middle frontal gyrus     | 8  | NeuroTrax| Memory          | Memory      | 0.379 | 0.023   |
| Right middle frontal gyrus    | 6  | NeuroTrax| Attention       | Attention   | 0.339 | 0.043   |
| Right superior medial frontal gyrus | 6  | Pen and Paper | RAVLT | Total | 0.393 | 0.016   |
| Right superior medial frontal gyrus | 6  | Pen and Paper | FAS         | Semantic   | 0.353 | 0.032   |
| Right supplementary motor area | 6  | Pen and Paper | RAVLT | Total | 0.394 | 0.016   |
| Right superior parietal gyrus | 7  | Pen and Paper | RAVLT | Total | 0.380 | 0.002   |

### Supplementary Table 5. Quality of life (SF-36 questionnaire) changes.

|                      | Control Group (N=33) | HBOT Group (N=29) | 3 months | Post-HBOT | 3 months | Baseline Comparison | Net Effect Size |
|----------------------|----------------------|-------------------|-----------|-----------|-----------|---------------------|----------------|
|                      | Baseline             | Control           | P-value   | Baseline  | Post-HBOT | P-value             | Size           |
| Physical function    | 86.97±15.41          | 89.25±12.99       | 0.55      | 84.28±14.16| 90.71±8.70| 0.08               | 0.53 | 0.66               |
| Physical limitations | 78.57±31.70          | 83.33±28.58       | 0.56      | 78.57±28.81| 88.09±16.99| 0.19               | 1   | 0.50               |
| Emotional limitations| 84.52±29.37          | 77.77±32.02       | 0.42      | 74.60±24.69| 76.19±30.08| 0.86               | 0.24 | 0.86               |
| Energy               | 69.10±16.10          | 69.44±14.36       | 0.93      | 62.61±15.21| 70.71±13.53| 0.07               | 0.16 | 0.75               |
| Emotional well being | 77.14±16.10          | 76.74±14.71       | 0.92      | 71.80±14.88| 78.28±13.53| 0.14               | 0.24 | 0.71               |
| Social function      | 87.05±17.17          | 88.42±16.60       | 0.76      | 84.52±20.50| 86.30±20.11| 0.77               | 0.64 | 0.69               |
| Pain                 | 81.42±19.92          | 83.61±19.34       | 0.68      | 79.16±17.12| 85.83±13.65| 0.17               | 0.68 | 0.65               |
| General health       | 75.0±16.83           | 79.62±16.28       | 0.30      | 74.52±14.30| 80.0±14.74| 0.23               | 0.92 | 0.93               |
Supplementary Table 6. Quality of life (SF-36 questionnaire) repeated measures analysis.

|                          | Main Effect of Group | Main Effect of Time | Interaction Effect (Group by Time) |
|--------------------------|----------------------|---------------------|------------------------------------|
|                          | $F$                  | $p$-value           | $F$                  | $p$-value |
| Physical function        | 0.108                | 0.743               | 8.266                | 0.006     | 2.406                | 0.128               |
| Physical limitations     | 0.096                | 0.758               | 2.025                | 0.162     | 0.580                | 0.450               |
| Emotional limitations    | 0.379                | 0.541               | 0.296                | 0.589     | 0.814                | 0.372               |
| Energy                   | 0.274                | 0.604               | 6.281                | **0.016** | 6.908                | **0.012**           |
| Emotional well being     | 0.089                | 0.767               | 3.005                | 0.090     | 2.733                | 0.105               |
| Social function          | 0.107                | 0.745               | 0.590                | 0.446     | 0.001                | 0.977               |
| Pain                     | 0.000                | 0.985               | 4.404                | **0.042** | 2.770                | 0.103               |
| General health           | 0.010                | 0.920               | 7.690                | **0.008** | 0.087                | 0.769               |